keyword
MENU ▼
Read by QxMD icon Read
search

Haploidentical stem cell transplantation

keyword
https://www.readbyqxmd.com/read/29222316/hla-donor-specific-antibodies-in-allogeneic-hematopoietic-stem-cell-transplantation-challenges-and-opportunities
#1
REVIEW
Douglas E Gladstone, Maria P Bettinotti
Allogenic hematopoietic stem cell recipients may have preformed antibodies directed against foreign HLA antigens. The use of partially HLA-mismatched allogeneic hematopoietic stem cell donors allows for the possibility of the presence of circulating HLA donor-specific antibodies (DSAs) in the recipient. The presence of DSAs at the time of stem cell infusion increases the risk of primary graft failure. More recently developed technology using solid phase immunoassays (SPIs) with fluorochrome-conjugated beads has greatly improved the ability to detect and classify DSAs...
December 8, 2017: Hematology—the Education Program of the American Society of Hematology
https://www.readbyqxmd.com/read/29212976/-congenital-leukemia-showing-lineage-switch-following-induction-chemotherapy-and-attaining-long-term-remission-after-hla-haploidentical-stem-cell-transplantation
#2
Kazuki Furudate, Yuri Okimoto, Kumiko Ando, Yuichi Taneyama, Hidemasa Ochiai, Harumi Kakuda
Congenital leukemia is a rare subgroup of childhood leukemia. Lineage switches in leukemic cells are relatively rare events, which have been occasionally reported in congenital leukemia. To the best of our knowledge, the survival of congenital leukemia patients with lineage switch has not been previously documented. This lack of documentation may be attributable to extremely poor prognosis of these patients. We describe a case of a newborn female with initial diagnosis of MLL-AF4 positive B-precursor acute lymphoblastic leukemia, who developed lineage switch to acute monocytic leukemia following the induction therapy...
2017: [Rinshō Ketsueki] the Japanese Journal of Clinical Hematology
https://www.readbyqxmd.com/read/29200154/rhinocerebral-mucormycosis-with-temporal-artery-thrombosis-in-an-adolescent-following-hla-haploidentical-stem-cell-transplantation
#3
Yuta Kawahara, Shoya Wada, Hitomi Nijima, Tomomi Hayase, Rieko Furukawa, Kentaro Ashizawa, Akira Morimoto
Rhinocerebral mucormycosis (RCM) can lead to internal carotid artery thrombosis. Here, we report the first case of RCM with temporal artery thrombosis following HLA-haploidentical stem cell transplantation in an adolescent presenting with low-grade fever, right mandibular pain, and right jaw claudication. This case suggests that RCM can cause temporal artery thrombosis and should be considered as a differential diagnosis in severely immunocompromised patients with maxillary sinusitis presenting with jaw claudication...
December 1, 2017: Journal of Pediatric Hematology/oncology
https://www.readbyqxmd.com/read/29197681/t-cell-replete-haploidentical-transplantation-with-post-transplant-cyclophosphamide-for-hodgkin-lymphoma-relapsed-after-autologous-transplant-reduced-incidence-of-relapse-and-of-chronic-gvhd-compared-to-hla-identical-related-donors
#4
Jacopo Mariotti, Raynier Devillier, Stefania Bramanti, Barbara Sarina, Sabine Furst, Angela Granata, Catherine Faucher, Samia Harbi, Lucio Morabito, Christian Chabannon, Carmelo Carlo-Stella, Reda Bouabdallah, Armando Santoro, Didier Blaise, Luca Castagna
Allogeneic hematopoietic stem cell transplant (SCT) represents a potential curative strategy for patients with Hodgkin lymphoma (HL) relapsing after autologous transplant (ASCT), but the incidence of disease relapse is still high. We performed a retrospective study on 64 patients with HL relapsing after ASCT in order to compare the outcome after HLA identical (HLAid-SCT, n=34) or haploidentical SCT with post-transplant cyclophosphamide (PT-Cy) (Haplo-SCT, n=30). All patients engrafted with a median time for neutrophil and platelet engraftment significantly shorter after HLAid compared with Haplo-SCT (14 vs 19 days and 11 vs 23 days, p<0...
November 29, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29191663/the-impact-of-single-dose-plerixafor-as-an-adjunct-to-g-csf-based-peripheral-blood-stem-cell-mobilisation-on-the-graft-composition-and-outcome-for-t-replete-haploidentical-pbsc-transplantation-with-post-transplantation-cyclophosphamide-a-comparative-study
#5
Sarita Rani Jaiswal, Prakash Bhakuni, Aby Joy, Nisha Murli, Priyanka Bharadwaj, Shamsur Zaman, Nedunchezian Murugayan, Suparno Chakrabarti
We conducted a prospective study on T and NK cell subset composition of the graft and the transplant outcomes inT-replete haploidentical transplantationwithsingle dose of subcutaneous Plerixafor(Px)added to G-CSF based mobilisation in allogeneic donors to collect 10 x 106/kg CD34+HSC at single apheresis. 26 donors received G-CSF+Px and 25 donors received G-CSF alone for mobilisation. Despite a significantly lower peripheral blood (PB) CD34+HSC on day 4 in the G-CSF+Px group [33(6-47) cells/µl vs 81(50-168) cells/µl in G-CSF group, p=0...
November 27, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29181178/development-of-lymphoma-from-the-donor-of-haploidentical-stem-cell-transplantation-a-case-report
#6
Linna Xie, Fang Zhou
Post-transplantation lymphoproliferative disease (PTLD) is a serious complication following hematopoietic stem cell transplantation (HSCT). The majority of the cases develop during the first year after the transplantation and are associated with reactivation of the Epstein-Barr virus (EBV); the EBV-induced lymphoproliferation usually includes donor-derived B cells. We herein describe the case of a 28-year-old female patient who developed EBV-negative PTLD, namely diffuse large B-cell lymphoma (DLBCL), 6 months after receiving a haploidentical HSCT from her father...
November 2017: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/29164981/successful-treatment-of-ph-all-with-hematopoietic-stem-cell-transplantation-from-the-same-hla-haploidentical-related-donor-of-previous-liver-transplantation
#7
Kensuke Sasaki, Yasuo Mori, Goichi Yoshimoto, Teppei Sakoda, Koji Kato, Kyoko Inadomi, Kenjiro Kamezaki, Katsuto Takenaka, Hiromi Iwasaki, Takahiro Maeda, Toshihiro Miyamoto, Koichi Akashi
No abstract text is available yet for this article.
November 22, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/29162400/an-alternative-method-for-custom-prime-a-case-report-of-successful-peripheral-blood-stem-cell-harvesting-from-two-low-weight-child-donors
#8
Ashraf Malek Mohammadi, Amir Hossein Norooznezhad, Parivash Aminian, Mohsen Nikbakht, Bahram Chahardouli, Shahrbano Rostami, Farhad Heshmati, Saeed Mohammadi, Ardeshir Ghavamzadeh
Allogeneic peripheral blood stem cell (APBSCs) transplantation is an effective treatment for hematological malignancies. However low-weight donor children meet some complications. In the current report, PBSCs were harvested from a 14-month-old child (9.8Kg) for a 6years old sibling recipient suffering from pre-B type of acute lymphoblastic leukemia (ALL) and also 24 months old male child donor (12Kg) for a haploidentical recipient suffering from acute myeloid leukemia (AML-M4EO). The PBSC harvesting was performed using Spectra™ Optia(®) apheresis software with continuous mononuclear cell (CMNC) procedure...
November 8, 2017: Transfusion and Apheresis Science
https://www.readbyqxmd.com/read/29155367/predicted-indirectly-recognizable-hla-epitopes-are-not-associated-with-clinical-outcomes-after-haploidentical-hematopoietic-stem-cell-transplantation
#9
Ming-Rui Huo, Dan Li, Ying-Jun Chang, Lan-Ping Xu, Xiao-Hui Zhang, Kai-Yan Liu, Xiao-Jun Huang
Haploidentical stem cell transplantation (haplo-SCT) provides an alternative method to cure patients with malignant and nonmalignant hematologic diseases who lack a human leukocyte antigen (HLA) matched related or unrelated donor. HLA disparity between donor and patient was the main reason causing lots of clinical immune response. The aim of this study was to investigate whether indirect recognition of mismatched HLA could predict the clinical outcomes in haplo-SCT. The probability of indirect recognition was predicted by the Predicted Indirectly ReCognizable HLA Epitopes (PIRCHE) model...
November 16, 2017: Human Immunology
https://www.readbyqxmd.com/read/29155317/treosulfan-fludarabine-conditioning-for-hsct-in-children-with-primary-immunodeficiency-uk-experience
#10
Mary A Slatter, Kanchan Rao, Intan Juliana Abd Hamid, Zohreh Nademi, Robert Chiesa, Reem Elfeky, Mark S Pearce, Persis Amrolia, Austen Worth, Terence Flood, Mario Abinun, Sophie Hambleton, Waseem Qasim, Hubert B Gaspar, Andrew J Cant, Andrew R Gennery, Paul Veys
We previously published results of 70 children who received treosulfan with cyclophosphamide (30) or fludarabine (40) before haematopoietic stem cell transplantation (HSCT) for Primary Immunodeficiency (PID). Toxicity was lower and T cell chimerism better in those receiving fludarabine, but numbers were relatively small and follow-up short. We now report outcome of 160 children who received homogeneous conditioning with treosulfan, fludarabine mostly with alemtuzumab (n=124). Median age at transplant was 1...
November 16, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29155271/t-cell-replete-haploidentical-transplantation-in-acute-myeloid-leukemia
#11
Luca Castagna, Raynier Devillier, Norbert Vey, Didier Blaise
In the last decade, the number of haploidentical transplantation is enhanced and this because of the widespread use of T cell replete platforms, developed worldwide. Acute myeloid leukemia is the main indication to perform an allogeneic stem cell transplantation. In this paper, we reviewed the clinical results obtained using T cell replete platforms in different clinical situations such as first or further complete remission, refractory disease, and elderly population. Overall, the toxic profile of T cell replete haploidentical transplantation is similar to transplantation from other donors, with some positive aspects such as a reduced incidence of chronic graft versus host disease...
November 16, 2017: Experimental Hematology
https://www.readbyqxmd.com/read/29137385/improved-outcome-of-haploidentical-transplantation-in-severe-aplastic-anemia-using-reduced-intensity-fludarabine-based-conditioning
#12
Wu Yamei, Luo Rongmu, Cao Yongbin, Si Yingjian, Li Xiaohong, Zhang Xiaomei, Yan Pei, Du Zhenlan, Wang Haitao, Wang Jing, Wang Bojing, Wu Xiaoxiong, Da Wanming
Significant improvements in hematopoietic stem cell transplantation (HSCT) with haploidentical family donors (HFD) have confirmed its therapeutic role in severe aplastic anemia (SAA) and led to the evolution of treatment algorithms. However, the optimal conditioning regimen for HFD-HSCT remains undefined, especially the dosage of cyclophosphamide (Cy). A total of 77 patients with SAA from two research centers, who received HFD-HSCT with reduced-intensity fludarabine + cyclophosphamide + thymoglobulin ± busulfan conditioning regimen plus third-party cells infusion were included in this study, of which 67 pairs had 4-5 loci mismatched...
October 13, 2017: Oncotarget
https://www.readbyqxmd.com/read/29132903/progressive-multifocal-leukoencephalopathy-in-patients-receiving-rituximab-and-cyclophosphamide-after-haplo-identical-t-cell-replete-transplantation-and-review-of-the-literature
#13
REVIEW
R Salem, R Massoud, S S Kanj, M Hamdan, R Salman, A Bazarbachi, J El-Cheikh
John Cunningham virus (JCV) reactivation, occurring mainly in immunocompromised patients, leads to progressive multifocal leukoencephalopathy, an uncommon but lethal disease. JCV reactivation after T-cell replete haploidentical stem cell transplantation, in the pre-cyclophosphamide era, is poorly represented in the literature. We therefore describe two cases of acute myeloid leukemia who developed JCV reactivation after receiving cyclophosphamide and rituximab post haploidentical stem cell transplantation, and review the literature, aiming to a better understanding of the disease course and its risk factors...
November 2017: Current Research in Translational Medicine
https://www.readbyqxmd.com/read/29128555/combined-haploidentical-and-umbilical-cord-blood-allogeneic-stem-cell-transplantation-for-high-risk-lymphoma-and-cll
#14
Jingmei Hsu, Andrew Artz, Sebastian A Mayer, Danielle Guarner, Michael R Bishop, Ronit Reich-Slotky, Sonali M Smith, June Greenberg, Justin Kline, Rosanna Ferrante, Adrienne A Phillips, Usama Gergis, Hongtao Liu, Wendy Stock, Melissa Cushing, Tsiporah B Shore, Koen van Besien
Limited studies have reported on outcomes for lymphoid malignancy patients receiving alternative donor allogeneic stem cell transplants. We have previously described combining CD34-selected haploidentical grafts with umbilical cord blood (haplo-cord) to accelerate neutrophil and platelet engraftment. Here, we examine the outcome of patients with lymphoid malignancies undergoing haplo-cord transplantation at the University of Chicago and Weill Cornell Medical College. We analyzed 42 lymphoma and CLL patients who underwent haplo-cord allogeneic stem cell transplantation...
November 8, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29127679/alternative-donor-unrelated-donor-transplants-for-the-%C3%AE-thalassemia-and-sickle-cell-disease
#15
Courtney D Fitzhugh, Allistair Abraham, Matthew M Hsieh
Considerable progress with respect to donor source has been achieved in allogeneic stem cell transplant for patients with hemoglobin disorders, with matched sibling donors in the 1980s, matched unrelated donors and cord blood sources in the 1990s, and haploidentical donors in the 2000s. Many studies have solidified hematopoietic progenitors from matched sibling marrow, cord blood, or mobilized peripheral blood as the best source-with the lowest graft rejection and graft versus host disease (GvHD), and highest disease-free survival rates...
2017: Advances in Experimental Medicine and Biology
https://www.readbyqxmd.com/read/29104089/rag-deficiency-with-alps-features-successfully-treated-with-tcr%C3%AE-%C3%AE-cd19-cell-depleted-haploidentical-stem-cell-transplant
#16
Emma Westermann-Clark, Alice Grossi, Francesca Fioredda, Stefano Giardino, Enrico Cappelli, Paola Terranova, Elena Palmisani, Jocelyn R Farmer, Zsofia Foldvari, Yasuhiro Yamazaki, Maura Faraci, Edoardo Lanino, Luigi D Notarangelo, Carlo Dufour, Isabella Ceccherini, Jolan E Walter, Maurizio Miano
No abstract text is available yet for this article.
November 2, 2017: Clinical Immunology: the Official Journal of the Clinical Immunology Society
https://www.readbyqxmd.com/read/29084206/myeloablative-conditioning-regimens-with-combined-of-haploidentical-and-cord-blood-transplantation-for-myelodysplastic-syndrome-patients
#17
P Ke, X-B Bao, X-H Hu, J Zhuang, X-J Wu, Y-J Liu, X-F He, D-P Wu, S-L Xue, X Ma
The purpose of this study was to evaluate the strategy of haploidentical (HID) stem cell combined with a small doses of umbilical cord blood (UCB) from a third-party donor transplantation (haplo-cord transplant) for treatment of myelodysplastic syndromes (MDS), by comparing with identical-sibling donor (ISD) transplantation. Eighty-five patients were included between January 2012 and December 2015, with a median 40 years old. Forty-eight patients received haplo-cord transplant and 37 patients received ISD transplant...
October 30, 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/29084024/haploidentical-stem-cell-transplantation-with-tcr-alpha-beta-and-cd19-depletion-in-a-case-of-unstable-hemoglobin-disease
#18
Karunakumar Kumar, Shobha Badiger, Sharat Damodar, Sunil Bhat
No abstract text is available yet for this article.
October 27, 2017: Transplantation
https://www.readbyqxmd.com/read/29076142/donor-derived-cd19-targeted-t-cell-infusion-induces-minimal-residual-disease-negative-remission-in-relapsed-b-cell-acute-lymphoblastic-leukaemia-with-no-response-to-donor-lymphocyte-infusions-after-haploidentical-haematopoietic-stem-cell-transplantation
#19
Yuhong Chen, Yifei Cheng, Pan Suo, Chenhua Yan, Yu Wang, Yao Chen, Wei Han, Lanping Xu, Xiaohui Zhang, Kaiyan Liu, Lungji Chang, Lei Xiao, Xiaojun Huang
Relapse is a common cause of failure in patients with B-cell acute lymphoblastic leukaemia (B-ALL) after haploidentical haematopoietic stem cell transplantation (haplo-HSCT), and non-responders to donor lymphoblastic infusion after HSCT have a very poor prognosis. Although donor-derived CD19-directed chimeric antigen receptor-modified (CAR) T cells can potentially cure leukaemia, their effectiveness and safety have not been confirmed in relapsed B-ALL cases after haplo-HSCT. Between January 2015 and January 2017, two and four patients each received one and two infusions of CAR T cells from haplo-HSCT donors...
October 26, 2017: British Journal of Haematology
https://www.readbyqxmd.com/read/29075259/virus-specific-t-cells-for-the-immunocompromised-patient
#20
REVIEW
Amy Houghtelin, Catherine M Bollard
While progress has been made in the treatment of both hematologic cancers and solid tumors, chemorefractory or relapsed disease often portends a dismal prognosis, and salvage chemotherapy or radiation expose patients to intolerable toxicities and may not be effective. Hematopoietic stem cell transplant offers the promise of cure for many patients, and while mismatched, unrelated or haploidentical donors are increasingly available, the recipients are at higher risk of severe immunosuppression and immune dysregulation due to graft versus host disease...
2017: Frontiers in Immunology
keyword
keyword
56859
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"